MetaVia Inc.MTVA
Metabolic21 cited findings · profile updated 2026-08-25
1.67 USDnot live — refreshed daily
About MetaVia Inc.
MetaVia Inc. (MTVA) is a company focused on metabolic therapeutic areas. The global obesity market size is currently $10B annually, with projections ranging from $80B–$130B+ annually. The MASH market opportunity for Vanoglipel (DA-1241) is $20B, and the global MASH market size is projected to be $20B–$35B+ annually.
MetaVia Inc. is developing DA-1726, which has shown a HbA1c change of -0.22 and a liver stiffness (VCTE) reduction of -23.7%. Other findings for DA-1726 include a HbA1c change of -0.8%, a Fasting Glucose reduction of -12.3 mg/dL, and a Waist Circumference reduction of -9.8 cm or -3.8 inches. Waist Circumference Change for DA-1726 has also been reported as -5.0% and -8.5%. The HbA1c for DA-1726 was 5.4%.
Vanoglipel (DA-1241) has demonstrated a significant HbA1c reduction. Specifically, 100 mg Vanoglipel showed a HbA1c reduction of -0.54 %p, and 100 mg Vanoglipel combined with 100 mg Sitagliptin resulted in a HbA1c reduction of -0.66 %p.
Compiled from the cited findings below — figures are as stated in each company's published technical reports and filings.
Key figures — cited
| MASH market opportunity | $20B for Vanoglipel (DA-1241) | MetaVia Inc. — SEC 8-K (2026-08-06), p.17 |
| Obesity market size | $10B annually Global | MetaVia Inc. — SEC 8-K (2026-08-06), p.3 |
| Obesity market size projection | $80B–$130B+ annually Global | MetaVia Inc. — SEC 8-K (2026-08-06), p.3 |
| MASH market size projection | $20B–$35B+ annually Global | MetaVia Inc. — SEC 8-K (2026-08-06), p.3 |
| HbA1c change | -0.22 for DA-1726 | MetaVia Inc. — SEC 8-K (2026-08-06), p.4 |
| Liver stiffness (VCTE) reduction | -23.7% for DA-1726 | MetaVia Inc. — SEC 8-K (2026-08-06), p.4 |
Key projects
- DA-1726
DA-1726 demonstrated a HbA1c change of -0.22 and a liver stiffness (VCTE) reduction of -23.7%.
- Vanoglipel (DA-1241)
Vanoglipel (DA-1241) showed a significant HbA1c reduction.
Every figure cites its source document. Prices refresh daily, not live. Informational only — not investment advice. Explore the Metabolic research library →